摘要
变应性支气管肺曲霉菌病(ABPA)是一种变应性肺部疾病,常表现为反复出现的肺部阴影伴外周血嗜酸性粒细胞增高。2013年国际人类和动物真菌学会(ISHAM)制定了ABPA诊断的新标准,并提出了外周血嗜酸性粒细胞的临界值。2017年中华医学会呼吸病学分会哮喘学组在ISHAM基础上结合中国实际情况,制定了适用于中国的ABPA诊断标准,将血嗜酸性粒细胞增高纳入其中。在治疗上,除常规的口服激素和抗真菌药联合治疗外,生物靶向治疗药物如抗IgE抗体、抗白细胞介素(IL)-5抗体、抗IL-4/13抗体均可使ABPA患者的血嗜酸性粒细胞水平降低。
Allergic bronchopulmonary aspergillosis(ABPA)is an allergic lung disease,which is often characterized by recurrent lung shadow with eosinophil increase in peripheral blood.In 2013,the International Society for Human and Animal Mycology(ISHAM)established a new diagnostic standard for ABPA and proposed a threshold for peripheral blood eosinophils.In 2017,on the basis of ISHAM,the Asthma Group of Respiratory Branch of Chinese Medical Association,combined with the actual situation of China,formulated the diagnostic criteria suitable for the diagnosis of ABPA in China,which included hypereosinophilia.In treatment,in addition to conventional oral hormone and antifungal therapy,biotargeted therapy drugs such as anti-IgE antibody,anti-interleukin(IL)-5 antibody and anti-IL-4/13 antibody can reduce the level of blood eosinophils in patients with ABPA.
作者
苏新明
SU Xin-ming(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2021年第12期1018-1020,1034,共4页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金重大项目(81770021)。
关键词
变应性支气管肺曲霉菌病
血嗜酸性粒细胞
诊疗
过敏反应
allergic bronchopulmonary aspergillosis
blood eosinophil
diagnosis and treatment
allergy
